ArticleJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2021
Mycosis fungoides and Sézary syndrome.
Article in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 18 citations in OpenAlex.
- Mycosis fungoides in a Mexican pediatric series: Clinical, immunophenotypic, and therapeutic features.Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- Article
- Growing Evidence for Distinct Clinical Features and Early Diagnostic Age of Cutaneous T-Cell Lymphoma in Saudi Arabia:Saudi medical journal · 2026Observational
- Authors' reply to: Commentary to: Lymphocytic UV autofluorescence: A novel ultraviolet-induced fluorescence dermoscopy finding in lichen nitidus-A series of 2 cases.JAAD case reports · 2026Article
- Localized palmar mycosis fungoides: A case report.Medicine · 2026Article
- Mogamulizumab plus etoposide in the management of mycosis fungoides with blood involvement: a case report.Therapeutic advances in hematology · 2026Article
- The diagnosis of early-stage mycosis fungoides: Views held by experts and non-experts in cutaneous lymphoma.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Article
- Article
- Diagnostic Utility of Molecular Analysis in Cutaneous T-Cell Lymphoma: Tunisian Series on Clonality of TCRG Gene Rearrangement.South Asian journal of cancer · 2025Article
- Cutaneous Squamous Cell Carcinoma Arising Within a Previously Irradiated Mycosis Fungoides Lesion.Cureus · 2024Article
- Article
- Review
- Article
- Diagnostic Approach to Adult Erythroderma: A Rare Case of Sezary Syndrome.Iranian journal of pathology · 2024Article
- A case report of refractory advanced-stage mycosis fungoides: successful treatment and improved patient quality of life with mogamulizumab.Therapeutic advances in hematology · 2024Article
- Multidisciplinary and personalized approach to the management of mycosis fungoides with chlormethine gel: a collection of clinical experiences.Drugs in context · 2024Article
- Case report: Canadian consensus on chlormethine gel use in mycosis fungoides-CTCL: literature review and real-world experience.Frontiers in medicine · 2024Article
- Tumor Stage Mycosis Fungoides with Lymph Node Involvement.Kansas journal of medicine · 2024Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycosis fungoides (MF) and Sézary syndrome (SS) are primary cutaneous T-cell lymphomas (CTCL) with not yet fully understood etiology and pathogenesis. Conceptually, MF and SS are classified as distinct entities arising from different T helper cell subsets. MF is the most common CTCL entity, while SS is very rare. MF presents clinically with patch, plaque and/or tumor stages, but can also evolve as erythroderma, which in turn is pathognomonic for SS. SS is characterized by a detectable tumor-cell burden (Sézary cells) in the peripheral blood consistent with advanced-stage disease and a poor prognosis. In early-stage disease of MF, which is the predominant form, the prognosis is generally favorable. However, in up to 30 % of patients, there is progression of skin lesions, which can ultimately lead to visceral involvement. The histological manifestation of MF can be subtle in early-stage disease and therefore a careful clinicopathological correlation is paramount. The treatment of MF/SS is dependent on the disease stage. Therapeutic options include both skin-directed and systemic regimens. Apart from allogeneic stem cell transplantation (alloSCT), there is as yet no curative therapy for MF/SS. Accordingly, the treatment approach is symptom oriented and aims to reduce the tumor burden and improve health-related quality of life. However, the therapeutic landscape for CTCL is constantly being expanded by the discovery of novel therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.